Pulse Biosciences (NASDAQ:PLSE) Trading 7.6% Higher – Still a Buy?

Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) traded up 7.6% on Tuesday . The company traded as high as $16.34 and last traded at $16.34. 33,479 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 200,741 shares. The stock had previously closed at $15.19.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a research note on Friday, September 20th.

Pulse Biosciences Price Performance

The business’s 50 day simple moving average is $17.38 and its 200 day simple moving average is $14.44.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same period in the previous year, the business earned ($0.19) earnings per share.

Institutional Investors Weigh In On Pulse Biosciences

Several hedge funds have recently added to or reduced their stakes in PLSE. BNP Paribas Financial Markets boosted its holdings in shares of Pulse Biosciences by 63.6% during the 1st quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock worth $66,000 after buying an additional 2,952 shares during the period. Quest Partners LLC acquired a new position in shares of Pulse Biosciences in the second quarter valued at approximately $91,000. Price T Rowe Associates Inc. MD bought a new position in shares of Pulse Biosciences during the first quarter worth approximately $88,000. Cetera Advisors LLC acquired a new stake in Pulse Biosciences during the 1st quarter worth approximately $109,000. Finally, Creative Planning boosted its stake in Pulse Biosciences by 113.9% in the 3rd quarter. Creative Planning now owns 21,910 shares of the company’s stock valued at $384,000 after purchasing an additional 11,667 shares during the period. Institutional investors and hedge funds own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.